

### AMENDMENTS TO THE CLAIMS

1. **(Currently amended)** A process for amplifying TALL-104 lymphocytes in a homogeneous culture system within a multi-chamber stack, ~~single fermentation unit~~ comprising:  
adding into the multi-chamber stack an inoculum of at least  $0.7 \times 10^6$  TALL-104 cells/ml in an initial volume from of 1/10 to 1/6 of the ~~multi~~multi-chamber stack ~~final~~ volume capacity and the same volume of fresh antibiotic-free complete medium;  
amplifying the cell number by adding a ~~volume of~~ complete medium volume corresponding to the volume ~~that~~ contained in the multi-chamber stack every 3-5 days;  
and  
recovering at least  $1 \times 10^9$  TALL-104 cells grown in homogeneous conditions.
2. **(Canceled)**
3. **(Canceled)**
4. **(Canceled)**
5. **(Currently amended)** The process as claimed in claim 1, wherein said process for amplifying TALL-104 lymphocytes is preceded by a process of pre-expansion in a flask until obtaining a number of cells in an amount from ~~0.7 to  $1 \times 10^8$~~   $3 \times 10^8$  to  $4 \times 10^8$ .
6. **(Currently amended)** The process as claimed in claim 1, wherein the cellular density of the inoculum is ~~at least~~  $0.75 \times 10^6$  cells/ml and, at the harvest time, the density is lower than  $2 \times 10^6$  cells/ml.
7. **(Previously presented)** The process as claimed in claim 1, wherein the multi-chamber stack is a 10-chamber unit.
8. **(Previously presented)** The process as claimed in claim 1, wherein said TALL-104 lymphocytes are genetically modified.
9. **(Canceled)**
10. **(Currently amended)** The process as claimed in Claim 1, wherein the complete culture medium in the multi-chamber stack amplification phase also comprises a maximum of 10% ~~maximum~~ human serum and interleukin in a concentration ~~comprised~~ from 80 to 120 IU/ml.
11. **(Previously presented)** The process as claimed in claim 10, wherein interleukin-2 is added to the cell culture every 48-90 hrs.
12. **(Canceled)**

13. **(Currently amended)** A process for the preparation of frozen bags of TALL-104 lymphocytes in an amount of at least  $1 \times 10^9$  cells comprising; ~~wherein the process according to Claim 1 is used~~

a. recovering at least  $1 \times 10^9$  TALL-104 cells grown in a homogeneous culture system in a multi-chamber stack according to claim 1;

b. centrifuging the TALL-104 cells; and

c. collecting the TALL-104 cells into frozen bags.

14. **(Currently amended)** The process as claimed in claim 13, wherein the bags are ~~is~~ sealed transversally to a bag filling collet at least in two points to create at least a sampling chamber containing a cell culture volume ranging from 0.1 to 1 ml, physically separated from the culture contained in the bag to perform quality controls.

15. **(Currently amended)** A process for the preparation of a therapeutic dose of at least  $1 \times 10^9$  TALL-104 lymphocytes in a homogeneous culture system comprising using the process according to Claim 1.

16.-24. **(Canceled)**

25. **(Previously presented)** The process as claimed in claim 10 wherein said complete culture medium comprises 4-6% human serum.

26. **(Previously presented)** A process according to claim 10, wherein said TALL-104 lymphocytes are genetically modified.

27. **(Canceled)**

28. **(Currently amended)** The process of claim 15, wherein the complete culture medium in the multi-chamber stack ~~cell-factory amplification amplification~~ phase also comprises a maximum of 10% maximum human serum and interleukin in a concentration from 80 to 120 IU/ml.